We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

THERMO FISHER SCIENTIFIC

  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System

By LabMedica International staff writers
Posted on 22 Sep 2021
Print article
Illustration
Illustration
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.

Thermo Fisher’s new Applied Biosystems QuantStudio Absolute Q Digital PCR System is the world’s first integrated digital PCR solution and is ideal for oncology, cell and gene therapy development and other research applications. dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy development and other research applications because its absolute quantification enables higher accuracy and precision. Thermo Fisher recently acquired Combinati and its cutting-edge dPCR technology to rapidly develop and commercialize it alongside an expanding portfolio of assays.

The dPCR technology that powers the QuantStudio Absolute Q solution is already in use by biotech companies and academic institutions for longitudinal monitoring of cancer-driving mutations in liquid biopsy, precise quantification of gene inserts for cell therapy development, and copy number variation studies for earlier identification of genetic conditions in newborns. Unlike complex, multi-instrument workflows required for traditional dPCR, the QuantStudio Absolute Q System uses microfluidic array technology and simplified workflows, designed to improve data accuracy and consistency. Hands-on time is just five minutes, minimizing the risk of user error.

"These early adopters of dPCR technologies have faced limitations, including error-prone operation, imprecision and poor turnaround times," said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. "For our customers, the QuantStudio Absolute Q Digital PCR System overcomes these limitations and provides an industry-best dPCR platform to enable accelerated innovation in cancer research, rare diseases and much more."

New
Gold Supplier
Fully Automated ELISA Workstation
EUROLabWorkstation ELISA
New
Microplate Reader
Sunrise
New
Clinical Chemistry Reagents
SEKURE Clinical Chemistry Reagents
New
ELISA Mini Workstation
Crocodile 5-in-one

Print article

Channels

Hematology

view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more

Microbiology

view channel
Illustration

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more

Technology

view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.